Want to see FR:ALNEV full AI Analyst Report?
ALNEV Stock Chart & Stats
€0.01
-€0.06(-6.03%)
At close: 4:00 PM EST
€0.01
-€0.06(-6.03%)
Day’s Range― - ―
52-Week Range€1.02 - €18,999.24
Previous CloseN/A
Volume950.00
Average Volume (3M)1.46M
Market Cap
€203.60K
Enterprise Value-€204.98K
Total Cash (Recent Filing)€571.79K
Total Debt (Recent Filing)€537.20K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding159,064
10 Day Avg. Volume1,456,964
30 Day Avg. Volume1,459,251
Financial Highlights & Ratios
PEG Ratio6.69
Price to Book (P/B)180.66
Price to Sales (P/S)20138.85
P/FCF Ratio-646.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low-leverage Balance SheetVery low reported leverage materially reduces near-term refinancing risk and preserves financial flexibility. For a cash-burning biotech this durable strength makes it easier to access debt or structure deals, improving runway options and lowering short-term solvency pressure.
Focused Immunotherapy R&D And IPA clear strategic focus on therapeutic vaccines and immunotherapies creates durable technical expertise and intellectual property potential. This specialist positioning can attract long-term partners, licensing deals and targeted investors if clinical data validates the platform.
Improving Cash-burn TrendAn improving cash-burn trajectory and less-negative free cash flow in 2025 signal operational discipline or timing improvements. Sustained progress here would lengthen runway, reduce immediate financing needs and allow management to advance key clinical programs longer without dilutive fundraising.
Bears Say
Persistent Negative Gross ProfitNegative gross profit across years indicates revenues do not cover direct costs, a structural barrier to profitability. For a biotech this implies commercial models or pricing aren't delivering scale, forcing dependence on financing or transformative cost reductions to achieve sustainable margins.
Sharp, Volatile Revenue DeclineA ~44% YoY revenue drop and multi-year volatility undermine scale economics and make forecasting difficult. This weakens internal funding for R&D, complicates partnership negotiations and increases the probability of repeated external financing, which can dilute shareholders and constrain strategy.
Ongoing Negative Operating Cash FlowConsistent negative operating and free cash flow means the company cannot self-fund operations and development. Over months this creates persistent reliance on capital markets or partners, raising execution risk and potential dilution if clinical progress does not materially improve cash generation prospects.
Neovacs SA News
ALNEV FAQ
What was Neovacs SA’s price range in the past 12 months?
Neovacs SA lowest stock price was €1.01 and its highest was €18999.24 in the past 12 months.
What is Neovacs SA’s market cap?
Neovacs SA’s market cap is €203.60K.
When is Neovacs SA’s upcoming earnings report date?
Neovacs SA’s upcoming earnings report date is Oct 22, 2026 which is in 109 days.
How were Neovacs SA’s earnings last quarter?
Neovacs SA released its earnings results on Mar 30, 2026. The company reported -€0.066 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.066.
Is Neovacs SA overvalued?
According to Wall Street analysts Neovacs SA’s price is currently Overvalued.
Does Neovacs SA pay dividends?
Neovacs SA does not currently pay dividends.
What is Neovacs SA’s EPS estimate?
Neovacs SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neovacs SA have?
Neovacs SA has 159,064 shares outstanding.
What happened to Neovacs SA’s price movement after its last earnings report?
Neovacs SA reported an EPS of -€0.066 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.446%.
Which hedge fund is a major shareholder of Neovacs SA?
Currently, no hedge funds are holding shares in FR:ALNEV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neovacs SA
Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages its proprietary Kinoid technology to develop treatments, particularly for chronic autoimmune and inflammatory disorders. Its lead candidate, IFNa Kinoid, an anti-interferon alpha vaccine, is currently undergoing Phase IIb clinical trials for systemic lupus erythematosus and Phase IIa trials for dermatomyositis, with further preclinical investigation for diabetes. Neovacs' pipeline also includes VEGF-Kinoid, which is in preclinical development for both age-related macular degeneration and various solid tumors. Additionally, IL-4/IL-13 Kinoid is in preclinical stages for allergy treatments. The company has a significant partnership with the Sunnybrook Research Institute, focusing on the preclinical advancement of VEGF Kinoid specifically for colorectal and ovarian cancers.